TYR and melanoma: To address the prognostic implications of the presence of late circulating melanoma cells, we decided to investigate the presence of tyrosinase mRNA by RT–PCR in the peripheral blood of stage IIB and III melanoma patients on high-dose adjuvant interferon a-2β at multiple sequential time points from initiation of treatment.